Enasidenib (Idhifa)

Mechanism of action

From the NCI Drug Dictionary: An orally available inhibitor of isocitrate dehydrogenase type 2 (IDH2), with potential antineoplastic activity. Upon administration, enasidenib specifically inhibits IDH2 in the mitochondria, which inhibits the formation of 2-hydroxyglutarate (2HG).

Diseases for which it is used

• Acute myeloid leukemia, IDH-mutated

History of changes in FDA indication

• 8/1/2017: Granted FDA regular approval "for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.

Also known as

• Code names: AG-221, CC-90007
• Brand name: Idhifa